DEA Publishes New Telemedicine Rules

On January 17, 2025, the Drug Enforcement Administration (DEA) unveiled two new rules outlining a regulatory pathway for clinicians' continued use of telemedicine to prescribe medications for the treatment of addiction: a final rule establishing the parameters for the use of telemedicine to prescribe buprenorphine for the treatment of opioid use disorder; and a proposed rule outlining a more limited special registration telemedicine pathway.

ASAM's summary of the two rules, including a list of FAQs, and a note about the effective dates can be found here.

ASAM's statement on the final rule on buprenorphine can be found here.